UPDATE 1 -AstraZeneca says U.S. to buy additional 500,000 Evusheld doses

The additional doses will add to previous purchase of 700,000 doses of the antibody therapy, which in December showed it retained neutralising activity against the highly transmissible Omicron coronavirus variant in a lab study. The U.S. Food and Drug Administration last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.


Reuters | Updated: 13-01-2022 11:01 IST | Created: 13-01-2022 10:58 IST
UPDATE 1 -AstraZeneca says U.S. to buy additional 500,000 Evusheld doses
Representative image Image Credit: Flickr

AstraZeneca said on Wednesday the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.

The company said the delivery of the doses was expected in the first quarter of 2022 and more details about the deal would be announced in the coming weeks. The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy, which in December showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.

The U.S. Food and Drug Administration last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines. It is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure, the company said.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback